Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lei, Shuying
HDM3014-301, NCT06648772: Efficacy and Safety of Roflumilast Cream 0.3% in Subjects with Plaque Psoriasis: a Phase 3 Study	Recruiting	3	189	RoW	Roflumilast Cream 0.3%, Zoryve, Vehicle cream	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Plaque Psoriasis	06/25	07/25
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis	Recruiting	3	351	RoW	Roflumilast Cream 0.15%, Vehicle cream	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Atopic Dermatitis (AD)	08/25	08/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lei, Shuying
HDM3014-301, NCT06648772: Efficacy and Safety of Roflumilast Cream 0.3% in Subjects with Plaque Psoriasis: a Phase 3 Study	Recruiting	3	189	RoW	Roflumilast Cream 0.3%, Zoryve, Vehicle cream	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Plaque Psoriasis	06/25	07/25
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis	Recruiting	3	351	RoW	Roflumilast Cream 0.15%, Vehicle cream	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Atopic Dermatitis (AD)	08/25	08/25